お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:体外診断 (IVD) 市場の成長機会・成長予測 (2020-2027年):製品&サービス・技術・用途・エンドユーザー・地域別
市場調査レポート
商品コード
1000330

体外診断 (IVD) 市場の成長機会・成長予測 (2020-2027年):製品&サービス・技術・用途・エンドユーザー・地域別

In Vitro Diagnostics Market by Product & Service, Technique, Application, and End User : Global Opportunity Analysis and Industry Forecast, 2020-2027

出版日: | 発行: Allied Market Research | ページ情報: 英文 381 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.93円
体外診断 (IVD) 市場の成長機会・成長予測 (2020-2027年):製品&サービス・技術・用途・エンドユーザー・地域別
出版日: 2021年02月17日
発行: Allied Market Research
ページ情報: 英文 381 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の体外診断 (IVD) の市場規模は予測期間中4.8%のCAGRで推移し、2019年の671億1100万米ドルから、2027年には910億9300万米ドルの規模に成長すると予測されています。

慢性疾患や感染症の増加に伴う検査数の増加、免疫疾患を発症しやすい高齢者人口の増加、個別化医療の利用の拡大、体外診断用製品、技術、ソフトウェアおよびサービスに関する技術的進歩などの要因が同市場の成長を推進しています。一方で、政府による厳しい規制、不利な償還方針などの課題が市場のさらなる成長を抑制すると予測されています。

当レポートでは、世界の体外診断 (IVD) の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、市場規模の推移・予測、製品&サービス・技術・用途・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義・範囲
  • 主な調査結果
  • 主な成功戦略
  • 主要企業の位置付け
  • ポーターズファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析
  • COVID-19:影響分析

第4章 市場分析・予測:製品・サービス別

  • 市場規模・予測:地域別
  • 市場分析:国別
    • 試薬
    • 機器
    • ソフトウェア・サービス

第5章 市場分析・予測:技術別

  • 市場規模・予測:地域別
  • 市場分析:国別
    • 免疫診断
      • 酵素免疫測定法 (ELISA)
      • 迅速検査
      • 酵素結合免疫スポット (ELISPOT)
      • ラジオイムノアッセイ (RIA)
      • ウエスタンブロット
    • 血液
    • 分子診断
      • ポリメラーゼ連鎖反応 (PCR)
      • 等温核酸増幅技術 (INAAT)
      • ハイブリダイゼーション
      • DNA診断
      • マイクロアレイ
      • その他
    • 組織診断
    • 臨床化学分析
      • BMP
      • 肝パネル
      • 腎臓プロファイル
      • 脂質プロファイル
      • 甲状腺機能パネル
      • 電解質パネル
      • 特殊化学品
    • その他

第6章 市場分析・予測:用途別

  • 市場規模・予測:地域別
  • 市場シェア分析:国別
    • 感染症
    • 心臓病
    • 免疫系疾患
    • 腎疾患
    • 胃腸疾患
    • その他

第7章 市場分析・予測:エンドユーザー別

  • 市場規模・予測:地域別
  • 市場シェア分析:国別
    • 独立系ラボ
    • 病院
    • 学術機関・医学部
    • ポイントオブケア検査
    • その他

第8章 市場分析・予測:地域・主要国別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向・成長要因・成長機会
    • 市場規模・予測:国別
    • 市場規模・予測:製品・サービス別
    • 市場規模・予測:技術別
    • 市場規模・予測:用途別
    • 市場規模・予測:エンドユーザー別

第9章 企業プロファイル

  • ABBOTT LABORATORIES
  • BECTON, DICKINSON AND COMPANY
  • BIOMERIEUX SA
  • BIO-RAD LABORATORIES, INC.
  • DANAHER CORPORATION (BECKMAN COULTER, INC.)
  • F. HOFFMANN-LA ROCHE AG.
  • QIAGEN N.V.
  • SIEMENS AG (SIEMENS HEALTHINEERS)
  • SYSMEX CORPORATION
  • THERMO FISHER SCIENTIFIC, INC.
図表

LIST OF TABLES

  • TABLE 01.IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027 ($MILLION)
  • TABLE 02.IN VITRO DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 03.IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 04.IN VITRO DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 05.IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027 ($MILLION)
  • TABLE 06.IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 07.IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY TYPE 2019-2027 ($MILLION)
  • TABLE 08.IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 09.IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY REGION, 2019-2027 ($MILLION)
  • TABLE 10.MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 11.IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 12.IN VITRO DIAGNOSTICS MARKET FOR TISSUE DIAGNOSTICS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 13.CLINICAL CHEMISTRY MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 14.IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2019-2027 ($MILLION)
  • TABLE 15.IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 16.IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 17.IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION,2019-2027 ($MILLION)
  • TABLE 18.IN VITRO DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2019-2027 ($MILLION)
  • TABLE 19.IN VITRO DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 20.IN VITRO DIAGNOSTICS MARKET FOR IMMUNE SYSTEM DISORDERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 21.IN VITRO DIAGNOSTICS MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 22.IN VITRO DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 23.IN VITRO DIAGNOSTICS MARKET FOR OTHER, BY REGION, 2019-2027 ($MILLION)
  • TABLE 24.IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 25.IN VITRO DIAGNOSTICS MARKET FOR STANDALONE LABORATORIES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 26.IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 27.IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC AND MEDICAL SCHOOL, BY REGION, 2019-2027 ($MILLION)
  • TABLE 28.IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY REGION, 2019-2027 ($MILLION)
  • TABLE 29.IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 30.GLOBAL IVD, PROMINENT APPLICATIONS, TECHNIQUES, & TECHNOLOGIES
  • TABLE 31.IN VITRO DIAGNOSTICS MARKET REVENUE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 32.NORTH AMERICA IVD, PROMINENT APPLICATIONS, TECHNIQUES, & TECHNOLOGIES
  • TABLE 33.NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 34.U.S. IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 35.U.S. IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 36.U.S. IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 37.U.S. IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 38.CANADA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 39.CANADA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 40.CANADA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 41.CANADA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 42.MEXICO IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 43.MEXICO IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 44.MEXICO IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 45.MEXICO IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 46.NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027 ($MILLION)
  • TABLE 47.NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027 ($MILLION)
  • TABLE 48.NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 49.NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 50.EUROPE IVD, PROMINENT APPLICATIONS, TECHNIQUES, & TECHNOLOGIES
  • TABLE 51.EUROPE IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 52.GERMANY IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 53.GERMANY IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 54.GERMANY IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 55.GERMANY IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 56.FRANCE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 57.FRANCE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 58.FRANCE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 59.FRANCE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 60.UK IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 61.UK IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 62.UK IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 63.UK IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 64.ITALY IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 65.ITALY IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 66.ITALY IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 67.ITALY IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 68.SPAIN IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 69.SPAIN IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 70.SPAIN IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 71.SPAIN IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 72.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 73.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 74.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 75.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 76.EUROPE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027 ($MILLION)
  • TABLE 77.EUROPE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027 ($MILLION)
  • TABLE 78.EUROPE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 79.EUROPE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 80.ASIA-PACIFIC IVD, PROMINENT APPLICATIONS, TECHNIQUES, & TECHNOLOGIES
  • TABLE 81.ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 82.INDIA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 83.INDIA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 84.INDIA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 85.INDIA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 86.CHINA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 87.CHINA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 88.CHINA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 89.CHINA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 90.JAPAN IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 91.JAPAN IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 92.JAPAN IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 93.JAPAN IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 94.AUSTRALIA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 95.AUSTRALIA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 96.AUSTRALIA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 97.AUSTRALIA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 98.SOUTH KOREA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 99.SOUTH KOREA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 100.SOUTH KOREA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 101.SOUTH KOREA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 102.REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 103.REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 104.REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 105.REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 106.ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027 ($MILLION)
  • TABLE 107.ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027 ($MILLION)
  • TABLE 108.ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 109.ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 110.LAMEA IVD, PROMINENT APPLICATIONS, TECHNIQUES, & TECHNOLOGIES
  • TABLE 111.LAMEA IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 112.BRAZIL IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 113.BRAZIL IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 114.BRAZIL IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 115.BRAZIL IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 116.SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 117.SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 118.SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 119.SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 120.SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 121.SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 122.SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 123.SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 124.REST OF LAMEA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027
  • TABLE 125.REST OF LAMEA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027
  • TABLE 126.REST OF LAMEA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027
  • TABLE 127.REST OF LAMEA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027
  • TABLE 128.LAMEA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2027 ($MILLION)
  • TABLE 129.LAMEA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019-2027 ($MILLION)
  • TABLE 130.LAMEA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 131.LAMEA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 132.ABBOTT: COMPANY SNAPSHOT
  • TABLE 133.ABBOTT: OPERATING SEGMENTS
  • TABLE 134.ABBOTT: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 135.BD : COMPANY SNAPSHOT
  • TABLE 136.BD : OPERATING SEGMENTS
  • TABLE 137.BD: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 138.BIOMERIEUX: COMPANY SNAPSHOT
  • TABLE 139.BIOMERIEUX: OPERATING SEGMENTS
  • TABLE 140.BIOMERIEUX: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 141.BIO-RAD: COMPANY SNAPSHOT
  • TABLE 142.BIO-RAD: OPERATING SEGMENTS
  • TABLE 143.BIO-RAD: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 144.DANAHER: COMPANY SNAPSHOT
  • TABLE 145.DANAHER: OPERATING SEGMENTS
  • TABLE 146.DANAHER: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 147.ROCHE: COMPANY SNAPSHOT
  • TABLE 148.ROCHE: OPERATING SEGMENTS
  • TABLE 149.ROCHE: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 150.QIAGEN: COMPANY SNAPSHOT
  • TABLE 151.QIAGEN: OPERATING SEGMENTS
  • TABLE 152.QIAGEN: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 153.SIEMENS: COMPANY SNAPSHOT
  • TABLE 154.SIEMENS: OPERATING SEGMENTS
  • TABLE 155.SIEMENS: PRODUCT PORTFOLIO
  • TABLE 156.SYSMEX: COMPANY SNAPSHOT
  • TABLE 157.SYSMEX: OPERATING SEGMENTS
  • TABLE 158.SYSMEX: PRODUCT AND SERVICE PORTFOLIO
  • TABLE 159.THERMO FISHER: COMPANY SNAPSHOT
  • TABLE 160.THERMO FISHER: OPERATING SEGMENTS
  • TABLE 161.THERMO FISHER SCIENTIFIC: PRODUCT AND SERVICE PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.IN-VITRO DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 02.TECHNIQUE MARKET SUB-SEGMENTATION
  • FIGURE 03.TOP INVESTMENT POCKETS
  • FIGURE 04.TOP WINNING STRATEGIES, 2017-2020
  • FIGURE 05.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017-2020
  • FIGURE 06.TOP WINNING STRATEGIES: BY YEAR, 2017-2020
  • FIGURE 07.TOP PLAYER POSITIONING, 2019
  • FIGURE 08.BARGANING POWER OF BUYERS
  • FIGURE 09.BARGANING POWER OF SUPPLIERS
  • FIGURE 10.THREAT OF SUBSTITUTIONS
  • FIGURE 11.THREAT OF NEW ENTRANTS
  • FIGURE 12.MODERATE COMPETITIVE RIVALRY
  • FIGURE 13.IMPACT ANALYSIS, IN-VITRO DIAGNOSTICS MARKET
  • FIGURE 14.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY, 2019 & 2027
  • FIGURE 15.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2019 & 2027
  • FIGURE 16.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2019 & 2027
  • FIGURE 17.IMMUNODIAGNOSTICS MARKET FOR ENZYME LINKED IMMUNOSORBENT ASSAY, 2019-2027 ($MILLION)
  • FIGURE 18.IMMUNODIAGNOSTICS MARKET FOR RAPID TESTS, 2019-2027 ($MILLION)
  • FIGURE 19.IMMUNODIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT (ELISPOT), 2019-2027 ($MILLION)
  • FIGURE 20.IMMUNODIAGNOSTICS MARKET FOR RADIOIMMUNOASSAY (RIA), 2019-2027 ($MILLION)
  • FIGURE 21.IMMUNODIAGNOSTICS MARKET FOR WESTERN BLOT, 2019-2027 ($MILLION)
  • FIGURE 22.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2019 & 2027
  • FIGURE 23.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2019 & 2027
  • FIGURE 24.MOLECULAR DIAGNOSTICS MARKET FOR POLYMERIZE CHAIN REACTION (PCR), 2019-2027 ($MILLION)
  • FIGURE 25.MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), 2019-2027 ($MILLION)
  • FIGURE 26.MOLECULAR DIAGNOSTICS MARKET FOR HYBRIDIZATION, 2019-2027 ($MILLION)
  • FIGURE 27.MOLECULAR DIAGNOSTICS MARKET FOR DNA DIAGNOSTICS, 2019-2027 ($MILLION)
  • FIGURE 28.MOLECULAR DIAGNOSTICS MARKET FOR MICROARRAY, 2019-2027 ($MILLION)
  • FIGURE 29.MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, 2019-2027 ($MILLION)
  • FIGURE 30.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2019 & 2027
  • FIGURE 31.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR TISSUE DIAGNOSTICS, BY COUNTRY, 2019 & 2027
  • FIGURE 32.CLINICAL CHEMISTRY MARKET FOR BASIC METABOLIC PANEL, 2019-2027 ($MILLION)
  • FIGURE 33.CLINICAL CHEMISTRY MARKET FOR LIVER PANEL, 2019-2027 ($MILLION)
  • FIGURE 34.CLINICAL CHEMISTRY MARKET FOR RENAL PROFILE, 2019-2027 ($MILLION)
  • FIGURE 35.CLINICAL CHEMISTRY MARKET FOR LIPID PROFILE, 2019-2027 ($MILLION)
  • FIGURE 36.CLINICAL CHEMISTRY MARKET FOR THYROID FUNCTION PANEL, 2019-2027 ($MILLION)
  • FIGURE 37.CLINICAL CHEMISTRY MARKET FOR ELECTROLYTE PANEL, 2019-2027 ($MILLION)
  • FIGURE 38.CLINICAL CHEMISTRY MARKET FOR SPECIALTY CHEMICALS, 2019-2027 ($MILLION)
  • FIGURE 39.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2019 & 2027
  • FIGURE 40.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR OTHERS IVD TECHNIQUES, BY COUNTRY, 2019 & 2027
  • FIGURE 41.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019 & 2027
  • FIGURE 42.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2019 & 2027
  • FIGURE 43.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY COUNTRY, 2019 & 2027
  • FIGURE 44.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR IMMUNE SYSTEM DISORDERS, BY COUNTRY, 2019 & 2027
  • FIGURE 45.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2019 & 2027
  • FIGURE 46.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019 & 2027
  • FIGURE 47.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR OTHER, BY COUNTRY, 2019 & 2027
  • FIGURE 48.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR STANDALONE LABORATORIES, BY COUNTRY, 2019 & 2027
  • FIGURE 49.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2019 & 2027
  • FIGURE 50.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC AND MEDICAL SCHOOLS, BY COUNTRY, 2019 & 2027
  • FIGURE 51.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2019 & 2027
  • FIGURE 52.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027
  • FIGURE 53.U.S. IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 54.CANADA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 55.MEXICO IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 56.EUROPEAN GERIATRIC POPULATION (ABOVE 65 YEARS), 2017
  • FIGURE 57.GERMANY IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 58.FRANCE IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 59.UK. IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 60.ITALY IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 61.SPAIN IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 62.REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 63.INDIA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 64.CHINA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 65.JAPAN IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 66.AUSTRALIA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 67.SOUTH KOREA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 68.REST OF ASIA-PACIFIC IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 69.BRAZIL IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 70.SAUDI ARABIA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 71.SOUTH AFRICA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 72.REST OF LAMEA IN-VITRO DIAGNOSTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 73.ABBOTT: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 74.ABBOTT: NET SALES SHARE, BY OPERATING SEGMENT, 2019 (%)
  • FIGURE 75.ABBOTT: NET SALES SHARE, BY REGION, 2019 (%)
  • FIGURE 76.BD: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 77.BD: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 78.BD: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 79.BIOMERIEUX: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 80.BIOMERIEUX: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 81.BIOMERIEUX: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 82.BIO-RAD: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 83.BIO-RAD: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 84.BIO-RAD: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 85.DANAHER: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 86.DANAHER: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 87.DANAHER: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 88.ROCHE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 89.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 90.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 91.QIAGEN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 92.QIAGEN: REVENUE SHARE BY PRODUCT AND SERVICE, 2019 (%)
  • FIGURE 93.QIAGEN: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 94.NET SALES, 2018-2020 ($MILLION)
  • FIGURE 95.SIEMENS: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 96.SIEMENS: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 97.SYSMEX: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 98.SYSMEX: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 99.SYSMEX: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 100.THERMO FISHER SCIENTIFIC: REVENUE, 2017-2019 ($MILLION)
  • FIGURE 101.THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 102.THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY REGION, 2019 (%)
目次
Product Code: LI_17336 / A00245

Title:
In Vitro Diagnostics Market by Product & Service (Reagents, Instruments, and Software & Services), Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Others), Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Others), and End User (Standalone Laboratory, Hospitals, Academic & Medical Schools, Point of Care, and Others): Global Opportunity Analysis and Industry Forecast, 2020-2027.

The global in vitro diagnostics market (IVD) was valued at $67,111 million in 2019, and is projected to reach $91,093 million at a CAGR of 4.8% from 2020 to 2027.

In vitro diagnostics (IVD) are defined as medical devices and reagents which are used to examine specimens such as blood, urine, stool, tissues, and other body fluids, which are derived from human body to detect diseases, conditions, and infections. The tests can be performed in stand-alone laboratory, hospital-based laboratory, and point-of-care centers. Some significant technologies incorporated in in vitro diagnostics include polymerase chain reaction (PCR), microarray techniques, sequencing technology, and mass spectrometry, which are used for test sample preparation. Moreover, other techniques that are used to perform in vitro diagnosis involve clinical chemistry, tissue diagnostics, immunodiagnostics, hematology, and others. For instance, in clinical chemistry various tests are performed in laboratory such as liver panel test, lipid profile, thyroid function test, and others. Furthermore, a thyroid function test is performed by collecting blood from a patient, which is then tested to check the level of thyroid stimulating hormone (TSH) in blood. Similarly, others such as polymerase chain reaction (PCR) are used to detect the presence of infectious diseases such as HIV, hepatitis, and others. In addition, constant innovations related to IVD products, service designs, and technology have encouraged doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines. For instance, some products that are used to perform various in vitro diagnostic tests using various technologies involve real time PCR detection systems, immunoassay systems, and others.

The major factor that contributes to the growth of the in vitro diagnostic market include surge in number of in vitro diagnostic tests, which is attributable to rise in incidences of chronic and infectious diseases. Furthermore, growth in geriatric population, which is prone to immunological disorders is another major factor that boosts the growth of the market. Moreover, rise in use of personalized medicines in treatment of various chronic diseases such as cancer also fuels the growth of the market. In addition, increase in technological advancements associated with in vitro diagnostic products, technologies, and software & services boosts the market growth. However, stringent government regulations and unfavorable reimbursement policies are anticipated to restrict the growth of the in vitro diagnostics market. On the contrary, high growth rate exhibited by developing economies present lucrative opportunities for key players in the in vitro diagnostics market during the forecast period.

The report segments the market across into product & service, technique, application, end user, and region. On the basis of product & service, the market is segmented into reagents, instruments, and services & software. On the basis of technique, it is categorized into immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, clinical chemistry, and others. In addition, the immunodiagnostics segment is further divided into types such as enzyme-linked immunosorbent assay (ELISA), rapid tests, enzyme-linked immunospot (ELISPOT), radioimmunoassay (RIA), and western blot. Moreover, the ELSIA segment is further divided into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA), and colorimetric immunoassay (CI). Similarly, the molecular diagnostics segment is divided into polymerize chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA diagnostics, microarray, and others.

The clinical chemistry segment is also further divided basic metabolic panel, liver panel, lipid profile, thyroid function panel, electrolyte panel, specialty chemicals, and others.

On the basis of application, the market segmented into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and others. On the basis of end user, it is categorized into standalone laboratories, hospitals, academics & medical schools, point-of-care, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players in the in vitro diagnostics market are Abbott Laboratories, Becton, Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation (Beckman Coulter, Inc.), F. Hoffmann-La Roche AG, Siemens AG, QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc.

KEY BENEFITS FOR STAKEHOLDERS

  • This report entails a detailed quantitative analysis along with the current global negative pressure wound therapy devices market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

  • By Product & Service
  • Reagents
  • Instruments
  • Software and Services
  • By Technique
  • Immunodiagnostics
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Chemiluminescence Immunoassay (CLIA)
  • Fluorescence immunoassay (FIA)
  • Colorimetric Immunoassay (CI)
  • Rapid Tests
  • Enzyme-Linked ImmunoSpot (ELISPOT)
  • Radioimmunoassay (RIA)
  • Western Blot
  • Hematology
  • Molecular Diagnostics
  • Polymerize Chain Reaction (PCR)
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Hybridization
  • DNA diagnostics
  • Microarray
  • Others
  • Tissue Diagnostics
  • Clinical Chemistry
  • Basic Metabolic Panel
  • Liver Panel
  • Lipid Profile
  • Thyroid Function Panel
  • Electrolyte Panel
  • Specialty Chemicals
  • Others
  • By Application
  • Infectious Diseases
  • Cancer
  • Cardiac Diseases
  • Immune System Disorders
  • Nephrological Diseases
  • Gastrointestinal Diseases
  • Others
  • By End User
  • Standalone Laboratories
  • Hospitals
  • Academic & Medical Schools
  • Point-of-Care
  • Others
  • By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

List of key players profiled in the report:

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation (Beckman Coulter, Inc.)
  • F. Hoffmann-La Roche AG
  • Siemens AG
  • QIAGEN N.V.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request):

  • DiaSorin
  • Johnson & Johnson

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Top winning strategies, 2019
  • 3.4.Top player positioning, 2019
  • 3.5.Porters five forces analysis
  • 3.6.Market dynamics
    • 3.6.1.Drivers
      • 3.6.1.1.Increase in incidences of chronic and infectious diseases
      • 3.6.1.2.Technological advancements in IVD
      • 3.6.1.3.Rise in adoption of in vitro diagnostic testing
      • 3.6.1.4.Increase in government expenditures on healthcare
      • 3.6.1.5.Increase in popularity of personalized medicine approach
    • 3.6.2.Restraint
      • 3.6.2.1.Unclear reimbursement policies
      • 3.6.2.2.Stringent regulatory policies
    • 3.6.3.Opportunities
      • 3.6.3.1.Potential opportunities for outsourcing
      • 3.6.3.2.Convergence of new technologies
    • 3.6.4.Impact Analysis
  • 3.7.COVID-19 Impact Analysis for In Vitro Diagnostics Market

CHAPTER 4:IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Reagents
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Instruments
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Software & Services
    • 4.4.1.Market size and forecast, by region
    • 4.4.2.Market analysis, by country

CHAPTER 5:IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Immunodiagnostics
    • 5.2.1.Market size and forecast, by type
      • 5.2.1.1.Enzyme-linked immunosorbent assay (ELISA)
      • 5.2.1.1.1.Market size and forecast, by type
      • 5.2.1.1.2.Chemiluminescence Immunoassay (CLIA)
      • 5.2.1.1.2.1.Market size and forecast
      • 5.2.1.1.3.Fluoresence immunoassay (FIA)
      • 5.2.1.1.3.1.Market size and forecast
      • 5.2.1.1.4.Colorimetric Immunoassay (CI)
      • 5.2.1.1.4.1.Market size and forecast
      • 5.2.1.2.Rapid Tests
      • 5.2.1.2.1.Market size and forecast
      • 5.2.1.3.Enzyme-linked immunospot (ELISPOT)
      • 5.2.1.3.1.Market size and forecast
      • 5.2.1.4.Radioimmunoassay (RIA)
      • 5.2.1.4.1.Market size and forecast
      • 5.2.1.5.Western blot
      • 5.2.1.5.1.Market size and forecast
    • 5.2.2.Market size and forecast, by region
    • 5.2.3.Market analysis, by country
  • 5.3.Hematology
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market share analysis, by country
  • 5.4.Molecular diagnostics
    • 5.4.1.Market size and forecast, by type
      • 5.4.1.1.Polymerize chain reaction (PCR)
      • 5.4.1.1.1.Market size and forecast
      • 5.4.1.2.Isothermal Nucleic acid amplification technology (INAAT)
      • 5.4.1.2.1.Market size and forecast
      • 5.4.1.3.Hybridization
      • 5.4.1.3.1.Market size and forecast
      • 5.4.1.4.DNA diagnostics
      • 5.4.1.4.1.Market size and forecast
      • 5.4.1.5.Microarray
      • 5.4.1.5.1.Market size and forecast
      • 5.4.1.6.Others
      • 5.4.1.6.1.Market size and forecast
    • 5.4.2.Market size and forecast, by region
    • 5.4.3.Market share analysis, by country
  • 5.5.Tissue diagnostics
    • 5.5.1.Market size and forecast, by region
    • 5.5.2.Market share analysis, by country
  • 5.6.Clinical chemistry
    • 5.6.1.Market size and forecast, by type
      • 5.6.1.1.Basic metabolic panel
      • 5.6.1.1.1.Market size and forecast
      • 5.6.1.2.Liver panel
      • 5.6.1.2.1.Market size and forecast
      • 5.6.1.3.Renal profile
      • 5.6.1.3.1.Market size and forecast
      • 5.6.1.4.Lipid profile
      • 5.6.1.4.1.Market size and forecast
      • 5.6.1.5.Thyroid function panel
      • 5.6.1.5.1.Market size and forecast
      • 5.6.1.6.Electrolyte panel
      • 5.6.1.6.1.Market size and forecast
      • 5.6.1.7.Specialty chemicals
      • 5.6.1.7.1.Market size and forecast
    • 5.6.2.Market size and forecast, by region
    • 5.6.3.Market share analysis, by country
  • 5.7.Others
    • 5.7.1.Market size and forecast, by region
    • 5.7.2.Market share analysis, by country

CHAPTER 6:IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Infectious Diseases
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market share analysis, by country
  • 6.3.Cancer
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market share analysis, by country
  • 6.4.Cardiac diseases
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market share analysis, by country
  • 6.5.Immune system disorders
    • 6.5.1.Market size and forecast, by region
    • 6.5.2.Market share analysis, by country
  • 6.6.Nephrological diseases
    • 6.6.1.Market size and forecast, by region
    • 6.6.2.Market share analysis, by country
  • 6.7.Gastrointestinal diseases
    • 6.7.1.Market size and forecast, by region
    • 6.7.2.Market share analysis, by country
  • 6.8.Others
    • 6.8.1.Market size and forecast, by region
    • 6.8.2.Market share analysis, by country

CHAPTER 7:IN VITRO DIAGNOSTICS MARKET, BY END USER

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.Standalone Laboratories
    • 7.2.1.Market size and forecast, by region
    • 7.2.2.Market share analysis, by country
  • 7.3.Hospitals
    • 7.3.1.Market size and forecast, by region
    • 7.3.2.Market share analysis, by country
  • 7.4.Academic and medical schools
    • 7.4.1.Market size and forecast, by region
    • 7.4.2.Market share analysis, by country
  • 7.5.Point-of-care testing
    • 7.5.1.Market size and forecast, by region
    • 7.5.2.Market share analysis, by country
  • 7.6.Others
    • 7.6.1.Market size and forecast, by region
    • 7.6.2.Market share analysis, by country

CHAPTER 8:IN VITRO DIAGNOSTICS MARKET, BY REGION

  • 8.1.Overview
    • 8.1.1.Market size and forecast
  • 8.2.North America
    • 8.2.1.Key market trends, growth factors, and opportunities
    • 8.2.2.Market size and forecast, by country
      • 8.2.2.1.U.S.
      • 8.2.2.1.1.U.S. in vitro diagnostics market, by product & service
      • 8.2.2.1.2.U.S. In vitro diagnostics market, by technique
      • 8.2.2.1.3.U.S. In vitro diagnostics market, by application
      • 8.2.2.1.4.U.S. In vitro diagnostics market, by end user
      • 8.2.2.2.Canada
      • 8.2.2.2.1.Canada iIn vitro diagnostics market, by product & service
      • 8.2.2.2.2.Canada In vitro diagnostics market, by technique
      • 8.2.2.2.3.Canada In vitro diagnostics market, by application
      • 8.2.2.2.4.Canada In vitro diagnostics market, by end user
      • 8.2.2.3.Mexico
      • 8.2.2.3.1.Mexico In vitro diagnostics market, by product & service
      • 8.2.2.3.2.Mexico In vitro diagnostics market, by technique
      • 8.2.2.3.3.Mexico In vitro diagnostics market, by application
      • 8.2.2.3.4.Mexico In vitro diagnostics market, by end user
    • 8.2.3.Market size and forecast, by product & service
    • 8.2.4.Market size and forecast, by technique
    • 8.2.5.Market size and forecast, by application
    • 8.2.6.Market size and forecast, by end user
  • 8.3.Europe
    • 8.3.1.Key market trends, growth factors, and opportunities
    • 8.3.2.Market size and forecast, by country
      • 8.3.2.1.Germany
      • 8.3.2.1.1.Germany In vitro diagnostics market, by product & service
      • 8.3.2.1.2.Germany In vitro diagnostics market, by technique
      • 8.3.2.1.3.Germany In vitro diagnostics market, by application
      • 8.3.2.1.4.Germany In vitro diagnostics market, by end user
      • 8.3.2.2.France
      • 8.3.2.2.1.France In vitro diagnostics market, by product & service
      • 8.3.2.2.2.France In vitro diagnostics market, by technique
      • 8.3.2.2.3.France In vitro diagnostics market, by application
      • 8.3.2.2.4.France In vitro diagnostics market, by end user
      • 8.3.2.3.UK
      • 8.3.2.3.1.UK In vitro diagnostics market, by product & service
      • 8.3.2.3.2.UK In vitro diagnostics market, by technique
      • 8.3.2.3.3.UK In vitro diagnostics market, by application
      • 8.3.2.3.4.UK In vitro diagnostics market, by end user
      • 8.3.2.4.Italy
      • 8.3.2.4.1.Italy In vitro diagnostics market, by product & service
      • 8.3.2.4.2.Italy In vitro diagnostics market, by technique
      • 8.3.2.4.3.Italy In vitro diagnostics market, by application
      • 8.3.2.4.4.Italy In vitro diagnostics market, by end user
      • 8.3.2.5.Spain
      • 8.3.2.5.1.Spain In vitro diagnostics market, by product & service
      • 8.3.2.5.2.Spain In vitro diagnostics market, by technique
      • 8.3.2.5.3.Spain In vitro diagnostics market, by application
      • 8.3.2.5.4.Spain In vitro diagnostics market, by end user
      • 8.3.2.6.Rest of Europe
      • 8.3.2.6.1.Rest of Europe In vitro diagnostics market, by product & service
      • 8.3.2.6.2.Rest of Europe In vitro diagnostics market, by technique
      • 8.3.2.6.3.Rest of Europe In vitro diagnostics market, by application
      • 8.3.2.6.4.Rest of Europe In vitro diagnostics market, by end user
    • 8.3.3.Market size and forecast, by product & service
    • 8.3.4.Market size and forecast, by technique
    • 8.3.5.Market size and forecast, by application
    • 8.3.6.Market size and forecast, by end user
  • 8.4.Asia-Pacific
    • 8.4.1.Key market trends, growth factors, and opportunities
    • 8.4.2.Market size and forecast, by country
      • 8.4.2.1.India
      • 8.4.2.1.1.India In vitro diagnostics market, by product & service
      • 8.4.2.1.2.India In vitro diagnostics market, by technique
      • 8.4.2.1.3.India In vitro diagnostics market, by application
      • 8.4.2.1.4.India In vitro diagnostics market, by end user
      • 8.4.2.2.China
      • 8.4.2.2.1.China In vitro diagnostics market, by product & service
      • 8.4.2.2.2.China In vitro diagnostics market, by technique
      • 8.4.2.2.3.China In vitro diagnostics market, by application
      • 8.4.2.2.4.China In vitro diagnostics market, by end user
      • 8.4.2.3.Japan
      • 8.4.2.3.1.Japan In vitro diagnostics market, by product & service
      • 8.4.2.3.2.Japan In vitro diagnostics market, by technique
      • 8.4.2.3.3.Japan In vitro diagnostics market, by application
      • 8.4.2.3.4.Japan In vitro diagnostics market, by end user
      • 8.4.2.4.Australia
      • 8.4.2.4.1.Australia In vitro diagnostics market, by product & service
      • 8.4.2.4.2.Australia In vitro diagnostics market, by technique
      • 8.4.2.4.3.Australia In vitro diagnostics market, by application
      • 8.4.2.4.4.Australia In vitro diagnostics market, by end user
      • 8.4.2.5.South Korea
      • 8.4.2.5.1.South Korea In vitro diagnostics market, by product & service
      • 8.4.2.5.2.South Korea In vitro diagnostics market, by technique
      • 8.4.2.5.3.South Korea In vitro diagnostics market, by application
      • 8.4.2.5.4.South Korea In vitro diagnostics market, by end user
      • 8.4.2.6.Rest of Asia-Pacific
      • 8.4.2.6.1.Rest of Asia-Pacific In vitro diagnostics market, by product & service
      • 8.4.2.6.2.Rest of Asia-Pacific In vitro diagnostics market, by technique
      • 8.4.2.6.3.Rest of Asia-Pacific In vitro diagnostics market, by application
      • 8.4.2.6.4.Rest of Asia-Pacific In vitro diagnostics market, by end user
    • 8.4.3.Market size and forecast, by product & service
    • 8.4.4.Market size and forecast, by technique
    • 8.4.5.Market size and forecast, by application
    • 8.4.6.Market size and forecast, by end user
  • 8.5.LAMEA
    • 8.5.1.Key market trends, growth factors, and opportunities
    • 8.5.2.Market size and forecast, by country
      • 8.5.2.1.Brazil
      • 8.5.2.1.1.Brazil In vitro diagnostics market, by product & service
      • 8.5.2.1.2.Brazil In vitro diagnostics market, by technique
      • 8.5.2.1.3.Brazil In vitro diagnostics market, by application
      • 8.5.2.1.4.Brazil In vitro diagnostics market, by end user
      • 8.5.2.2.Saudi Arabia
      • 8.5.2.2.1.Saudi Arabia In vitro diagnostics market, by product & service
      • 8.5.2.2.2.Saudi Arabia In vitro diagnostics market, by technique
      • 8.5.2.2.3.Saudi Arabia In vitro diagnostics market, by application
      • 8.5.2.2.4.Saudi Arabia In vitro diagnostics market, by end user
      • 8.5.2.3.South Africa
      • 8.5.2.3.1.South Africa In vitro diagnostics market, by product & service
      • 8.5.2.3.2.South Africa In vitro diagnostics market, by technique
      • 8.5.2.3.3.South Africa In vitro diagnostics market, by application
      • 8.5.2.3.4.South Africa In vitro diagnostics market, by end user
      • 8.5.2.4.Rest of LAMEA
      • 8.5.2.4.1.Rest of LAMEA In vitro diagnostics market, by product & service
      • 8.5.2.4.2.Rest of LAMEA In vitro diagnostics market, by technique
      • 8.5.2.4.3.Rest of LAMEA In vitro diagnostics market, by application
      • 8.5.2.4.4.Rest of LAMEA In vitro diagnostics market, by end user
    • 8.5.3.Market size and forecast, by product & service
    • 8.5.4.Market size and forecast, by technique
    • 8.5.5.Market size and forecast, by application
    • 8.5.6.Market size and forecast, by end user

CHAPTER 9:COMPANY PROFILES

  • 9.1.ABBOTT LABORATORIES
    • 9.1.1.Company overview
    • 9.1.2.Company snapshot
    • 9.1.3.Operating business segments
    • 9.1.4.Product and service portfolio
    • 9.1.5.Business performance
    • 9.1.6.Key strategic moves and developments
  • 9.2.BECTON, DICKINSON AND COMPANY
    • 9.2.1.Company overview
    • 9.2.2.Company snapshot
    • 9.2.3.Operating business segments
    • 9.2.4.Product and service portfolio
    • 9.2.5.Business performance
    • 9.2.6.Key strategic moves and developments
  • 9.3.BIOMERIEUX SA
    • 9.3.1.Company overview
    • 9.3.2.Company snapshot
    • 9.3.3.Operating business segments
    • 9.3.4.Product and service portfolio
    • 9.3.5.Business performance
    • 9.3.6.Key strategic moves and developments
  • 9.4.BIO-RAD LABORATORIES, INC.
    • 9.4.1.Company overview
    • 9.4.2.Company snapshot
    • 9.4.3.Operating business segments
    • 9.4.4.Product and service portfolio
    • 9.4.5.Business performance
    • 9.4.6.Key strategic moves and developments
  • 9.5.DANAHER CORPORATION (BECKMAN COULTER, INC.)
    • 9.5.1.Company overview
    • 9.5.2.Company snapshot
    • 9.5.3.Operating business segments
    • 9.5.4.Product and service portfolio
    • 9.5.5.Business performance
    • 9.5.6.Key strategic moves and developments
  • 9.6.F. HOFFMANN-LA ROCHE AG.
    • 9.6.1.Company overview
    • 9.6.1.Company snapshot
    • 9.6.2.Operating business segments
    • 9.6.3.Product and service portfolio
    • 9.6.4.Business performance
    • 9.6.5.Key strategic moves and developments
  • 9.7.QIAGEN N.V.
    • 9.7.1.Company overview
    • 9.7.2.Company snapshot
    • 9.7.3.Operating business segments
    • 9.7.4.Product and service portfolio
    • 9.7.5.Business performance
    • 9.7.6.Key strategic moves and developments
  • 9.8.SIEMENS AG (SIEMENS HEALTHINEERS)
    • 9.8.1.Company overview
    • 9.8.2.Company snapshot
    • 9.8.3.Operating business segments
    • 9.8.4.Product portfolio
    • 9.8.5.Business performance
    • 9.8.6.Key strategic moves and developments
  • 9.9.SYSMEX CORPORATION
    • 9.9.1.Company overview
    • 9.9.2.Company snapshot
    • 9.9.3.Operating business segments
    • 9.9.4.Product and service portfolio
    • 9.9.5.Business performance
  • 9.10.THERMO FISHER SCIENTIFIC, INC.
    • 9.10.1.Company overview
    • 9.10.2.Company snapshot
    • 9.10.3.Operating business segments
    • 9.10.4.Product and service portfolio
    • 9.10.5.Business performance
    • 9.10.6.Key strategic moves and developments
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.